Background-Percutaneous pulmonary valve implantation using a stent-based bioprosthetic valve provides an alternative to surgery in select patients. Systemic infections in Melody valve-implanted patients with and without identified valve involvement have been reported, yet the incidence is unknown, and risk factors remain unidentified. Methods and Results-Between 2007 and 2012, a total of 147 consecutive patients with congenital heart disease underwent Melody percutaneous pulmonary valve implantation at our institution. Demographic and clinical variables were collected at baseline and at follow-up and analyzed as predictors. The occurrence of bloodstream infection (BSI), defined as a bacterial infection treated with ≥4 weeks of antibiotics, served as our primary outcome. The mean age at implantation for the study population was 21.5±11 years, and tetralogy of Fallot was the cardiac condition in 59%. During a median followup of 19 months, 14 patients experienced BSI (9.5%; 95% confidence interval, 5.3%-15%). Of these, 4 (2.7%) patients had Melody valve endocarditis. Two patients died during the event, neither of whom had known valve involvement. The median procedure to infection time was 15 months (range, 1-56). In univariate analysis, male sex, previous endocarditis, in situ stents in the right ventricular outflow tract, and presence of outflow tract irregularities at the implant site were associated with BSI occurrence. Conclusions-In this cohort, 9.5% of patients who underwent Melody percutaneous pulmonary valve implantation experienced subsequent BSI, occurring 1 to 56 months after implant, and 2.7% of patients had prosthetic endocarditis. Our findings suggest that patient and nonvalve anatomic factors may be associated with BSI after percutaneous pulmonary valve implantation. (Circ Cardiovasc Interv. 2013;6:301-310.)
P ercutaneous pulmonary valve implantation (PPVI) is a valuable therapeutic option for right ventricular to pulmonary artery conduit failure in selected patients. Percutaneous implantation of a valve in the right ventricular outflow tract (RVOT) offers a nonsurgical alternative in situations that might otherwise require repeat surgical intervention. The Melody valve (Medtronic Inc, Minneapolis, MN), a glutaraldehydefixed bovine jugular vein valve mounted on a platinum, balloon-expandable stent, 1 is currently the only approved device for PPVI. Reports of short-and medium-term outcomes suggest substantial hemodynamic and clinical improvement, low reintervention rates, and acceptable safety profile. [2] [3] [4] [5] Prosthetic valve endocarditis is an infrequent, but potentially lethal event, occurring primarily in the aortic and mitral positions. [6] [7] [8] [9] [10] [11] [12] Prosthetic valve endocarditis is usually preceded by systemic bacteremia, with subsequent infection at the site of the prosthesis. Both native and prosthetic pulmonic valve endocarditis are rare, with reported incidences of 0.6% to 1% 13 and 1.2% to 2%, 14, 15 respectively. Recent, isolated reports of bacterial infections affecting Melody valve-implanted patients [16] [17] [18] have not yet led to a broader review of the incidence of these bloodstream infections (BSI) in this population. The aim of this study was to evaluate the incidence of BSI occurring in patients who underwent Melody PPVI in a single center, as well as the outcomes of these events and associated risk factors.
Methods

Study Populations and Data Collection
This analysis includes all patients who underwent Melody PPVI at our institution between January 2007 and June 2012, either because of RVOT conduit or bioprosthetic valve dysfunction. This time period encompasses the enrollment of 2 sequential study groups: patients recruited and implanted before January 2010 to the Investigational Device Exemption study, and patients treated through June 2012 under the Humanitarian Device Exemption approval. The protocols of the original study, including the inclusion and exclusion criteria, were previously reported. 3, 19 Screening for infections before PPVI was performed routinely. All patients underwent interview/parental interview, vital sign assessment, and comprehensive physical examination both on the day before and on the day of the procedure. In addition, complete blood count was obtained on the day before the procedure. In the case of suspected infection, the procedure was deferred. Patients received 3 prophylactic antibiotic doses (1 before and 2 after the procedure), usually of Cefazolin. In the case of allergy, 1 dose of Vancomycin was administered. According to institutional practice, patients were prescribed aspirin and were recommended to observe endocarditis prophylaxis for 6 months after the procedure. Infection control recommendations for catheterization laboratories 20 were fully implemented during all procedures, including specifications about patient preparation, hand hygiene, procedural attire, and environmental conditions. Manufacturer-provided instructions about valve handling at the catheterization laboratory were strictly followed.
Prospectively collected data on the patients implanted with a Melody valve included demographic variables, cardiac condition, comorbidities, procedure-related data, and follow-up imaging results. Retrospectively collected data were obtained by reviewing medical records; these included information on previous endocarditis events, use of antiaggregants, and the overall number of stents in the RVOT. Catheterization reports and angiography films were also evaluated in a retrospective fashion.
As an additional analysis to assess the incidence of infections associated with nonvalved, bare metal stent (BMS) in the RVOT, we compared the cohort of the Melody-implanted patients with a historical group of BMS-implanted patients. 21 These patients had RVOT stent placed before 2007, primarily for indications of RVOT obstruction. Data for this group were obtained retrospectively through medical record review.
Definitions
A BSI event was defined as positive microorganism growth in 2 separate blood cultures. Infective endocarditis was defined in accordance with the Duke criteria: major and minor diagnostic criteria for infective endocarditis were attributed to patients who experienced BSI. 22 To assess the postimplantation degree of RVOT obstruction in follow-up, echocardiographic gradients were obtained. For patients with BSI, the gradient obtained at the study preceding the infection event (rather than at the time of BSI, all obtained>1 month before BSI occurrence) is reported, so as to avoid the potential for high gradients related to obstructing infectious lesions on the valve. Chronic comorbidities were defined as chronic health conditions necessitating periodic evaluation and continuous medical (drug or mechanical device) treatment.
The study protocol, including waiver of consent for retrospective medical record review and angiographic reviews, was approved by the Institutional Committee for Clinical Investigation.
Fluoroscopic and Angiographic Features
We reviewed the fluoroscopic and angiographic appearance of the RVOT, with an eye toward its anatomic configuration and luminal irregularities at the level of the valve stent, and of the burden of hardware present (primarily previously implanted stents). The following angiographic criteria were characterized:
1. Outflow tract wall irregularities: luminal outpouchings of the RVOT conduit extrinsic to the Melody stent and present at the conclusion of the PPVI procedure. These irregularities were evaluated in 2 angiographic projections, for (a) maximal length, (b) maximal depth, the greatest distance from the outer surface of the Melody stent to the endoluminal surface, and (c) circumferential involvement, scored 0 to 4 based on visibility in the 4 angiographic aspects of the stent (ie, left, right, anterior, and posterior, Figure 1 ). 2. The presence of a contained tear at the site of valve implantation at the conclusion of the procedure. 3. The presence of a perivalvular leak at the conclusion of the procedure.
To evaluate these variables, all catheterization films of the entire Melody PPVI cohort were reviewed in a fashion blinded to the outcome.
Study End Points
The end point of this study was defined as postimplantation occurrence of culture-positive BSI treated with ≥4 weeks of antibiotic therapy. Valve involvement was also determined by visualization of vegetations on the valve either by transesophageal echocardiography (TEE) or transthoracic echocardiography (TTE), in consistence with the Duke criteria.
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Statistical Analysis
Continuous demographic, clinical, and procedural variables of study subjects are presented with medians (25th and 75th percentiles, interquartile range). Categorical data are presented as frequencies and percentages. Variables stratified by the occurrence of BSI in patients who had a percutaneous Melody valve implantation were compared using Fisher exact test for categorical variables and Mann-WhitneyWilcoxon tests for continuous variables. Once patients with BSI were identified, a case-control analysis was performed, with cases of BSI matched by follow-up duration to patients without BSI. The matched groups were compared using Fisher exact test for categorical variables and t tests or Mann-Whitney-Wilcoxon tests for continuous variables.
WHAT IS KNOWN
• Percutaneous implantation of a prosthetic pulmonic valve can be used as a substitute to surgical pulmonic valve replacement in select patients.
• The percutaneous procedure is considered safe, and the short-and medium-term outcomes suggest good hemodynamic results.
WHAT THE STuDy ADDS
• Occurrences of systemic bacterial infection and of prosthetic valve endocarditis are possible long-term adverse events of this procedure because, in our series, 9.5% of the patient population experienced a systemic infection, and 3% of the patient population had frank endocarditis.
• Systemic bacterial infections and endocarditis of the prosthetic pulmonic valve can be life risking, and explantation of the infected valve may be required at the time of the infection. An increased mortality risk may be associated with certain organisms because, in our series, all mortalities occurred in patients with Staphylococcus aureus infections.
• Certain patient characteristics may be associated with the occurrence of systemic bacterial infections, including male sex, previous endocarditis events, high number of stents at the right ventricular outflow tract, and altered anatomy of the right ventricular outflow tract.
To determine whether the incidence of infection may have changed over the period of the study, the Kaplan-Meier method was used to estimate freedom from infection for the cohorts of patients implanted before and after January 2010. Time was measured from date of implantation to date of infection, or to date of last follow-up in patients who did not experience an infection. Comparison of time with infection was performed using the log-rank test.
The PPVI cohort was compared with a cohort from a previously reported historical control group of patients with nonvalved BMS implantation (n=219). 21 Freedom from implantation to infection was estimated using the Kaplan-Meier method, and compared between groups using the log-rank test. A P value <0.05 was used to denote statistical significance. Analyses were performed with Statistical Analysis System software version 9.3 (SAS Institute Inc, Cary, NC).
Results
From January 2007 until June 2012, 149 consecutive patients underwent Melody PPVI at our institution. Of these, 2 died in the immediate postprocedural period of noninfectious causes. The remaining 147 patients (80 males, 54%) comprised the study population, with 50 patients (34%) having valve implant before January 2010 (Investigational Device Exemption study, 47 patients, or compassionate use, 3 patients). Clinical data, echocardiograms, and angiograms for review were available for all patients. The median age at implantation was 19 years (range, 3-59), and the underlying cardiac diagnosis was tetralogy of Fallot with or without pulmonary artery atresia in 59%.
During a median clinical follow-up of 19 months (range, 1-63), 14 patients experienced an outcome event (9.5%, 95% confidence interval, 5.3% to 15%). Median interval from procedure to BSI was 15 months (range, 1-56 months). Detailed data about the infection events, treatment, and outcomes are presented in Table 1 .
Common presenting symptoms included fever and malaise, yet 2 patients presented in a state of severe shock. Blood cultures revealed Streptococci in 7 patients (50%), Staphylococci in 6 (43%), and Haemophilus in 1 patient. Four patients had definite endocarditis, meeting 2 major and 2 minor Duke criteria points, and 10 had possible endocarditis, meeting 1 major risk point (all for positive blood cultures) and 2 minor risk points (all for temperature >38 o C and predisposition).
Two mortalities occurred as consequence of the infection, which were both caused by methicillin-resistant Staphylococcus aureus, and did not have documented valve involvement. Postmortem evaluation was performed in 1, and gross inspection of the valve failed to identify valve vegetations.
All patients but 1 were treated with an intravenous antibiotic regimen for ≥4 weeks. The exception was a patient with a history of extremely difficult venous access, whose peripherally inserted central catheter was inadvertently pulled after only 2 weeks of intravenous treatment. He subsequently continued on oral antibiotics for 2 additional weeks. None of the patients had a central catheter in place at the time of the index infection.
Echocardiographic Findings at the Time of BSI
Patients with BSI underwent TEE, with the exception of 2 in whom TTE was deemed sufficient for valve visualization. After infections follow-up TEEs were not performed in both cases: 1 patient died during the infection and the other underwent serial follow-up TTEs, which were again of sufficient imaging quality for visualization of his Melody valve. In 4 patients (2.7%), both TTE and TEE demonstrated evidence of valve involvement as an oscillating intracardiac mass. Of these, 1 valve was explanted, whereas the other 3 patients were treated medically with subsequent resolution of the vegetations in 2. Post-BSI echocardiography was unavailable for the fourth patient. The remaining 8 patients underwent both TEE and TTE studies at the time of the infection that were nondiagnostic for the presence of valve involvement. The TEEs did not provide additional data to that already obtained from TTEs in these patients.
To learn more of the hemodynamic alterations at the level of the RVOT at the time of BSI, we evaluated for the pressure gradients, as well as for the presence of worsening regurgitation. The findings were compared with the images obtained from the last studies before the infection. Increased peak and the mean pressure gradients across the RVOT were recorded in all 14 patients, with a median increased of 19.5 and of 12 mm Hg, respectively (Table 1 ). There was no significant difference in the gradient change between patients who did and did not have documented valve involvement. None of the patients had evidence of worsening valve regurgitation at the time of the infection.
Parameters Associated With Occurrence of BSI
Baseline and follow-up demographic, angiographic, and hemodynamic variables of the study patients stratified by BSI occurrence are presented in Table 2 .
Preprocedural Risk Factors
Two important demographic variables were found to be associated with BSI occurrence. First, nearly all the patients that experienced BSI were male (93%) as compared with an even sex distribution in the non-BSI group (50%; P=0.003). Second, a significantly higher proportion of patients in the BSI group experienced an endocarditis event before PPVI (36% versus 7%; P=0.005). On investigation of these previous events, we found that all occurred >1.5 years before the PPVI procedure. Details of the infection site and causative organisms were available for 3 out of 5 patients: the organisms were different from the BSI-causing organisms in all 3 and, in 2 of them, the RVOT conduit was not replaced after the first endocarditis event. No differences existed between the groups in terms of the cardiac diagnostic category, the type of RVOT conduit, mode of conduit failure, or the presence of other intracardiac devices (eg, closure devices or pacemaker leads).
Procedure-Related Risk Factors
The median sheath-to-sheath time was longer in the BSI group (153 versus 120 minutes; P=0.006), yet this did not seem to be attributable to additional interventions during the procedure (P=0.25; Table 2 ). Residual RVOT gradients measured at the catheterization laboratory at the conclusion of the procedure were minimally higher in the BSI group (19 versus 15 mm Hg; P=0.03). The anatomic configuration of the RVOT and the amount of hardware in it differed between the groups: patients with BSI had more RVOT stents at the conclusion of the index procedure (median 2 versus median 0; P<0.001; Figure 2) . Results of the angiographic review indicated that presence of irregularities at the outflow tract outer wall were somewhat more common in the BSI group (50% versus 23%; P=0.05), and were deeper than those found in patients without BSI (median max depth 1.5 versus 1.0 cm; P=0.05). No differences existed in the occurrence of contained tears or in the occurrence of perivalvular leak.
Postprocedural Risk Factors
Late follow-up mean gradients across the RVOT were higher in the BSI group (26 versus 14 mm Hg in echocardiographic evaluation; P<0.001) in the absence of any apparent effect of anticoagulant use. As would be expected, BSI occurrence was associated with longer follow-up; patients who had an infection event were followed for a median of 32 versus 18 months follow-up duration among those with no BSI (P=0.01).
Matching Analysis
The 14 patients who had BSI were matched in a 2:1 fashion for follow-up duration with control patients from the cohort of the Melody-implanted patients without BSI (Table 3 ). The findings in this analysis were mostly consistent with those obtained in the entire cohort analysis: BSI occurrence was associated with male sex, longer procedure times, greater number of stents in the RVOT, and higher RVOT gradients. In this analysis, previous endocarditis was of borderline significance (P=0.09). The presence of outflow tract irregularities was not found to be associated with BSI in this analysis, yet similar to the primary analysis, there was a statistically significant association between deeper irregularities and outcome occurrence.
Patient Characteristics and BSI Occurrence by Era
Although the incidence of infections during follow-up was 16% (8 out of 50 patients) among patients enrolled in the Investigational Device Exemption trial and 6.2% (6 out of 97 of patients) among patients treated under the Humanitarian Device Exemption approval, the rates of infection did not seem to change significantly during the study period. KaplanMeier estimates of event-free survival among the 2 groups are shown in Figure 3 . The cumulative probability of survival without infection for the earlier-recruited patients was 70% Table 1 . AS indicates aortic stenosis; DORV, double outlet right ventricle; PA, pulmonic atresia; PPVI, percutaneous pulmonary valve implantation; RVOT, right ventricular outflow tract; TGA, transposition of the great arteries; and TOF, tetralogy of Fallot.
*Defined as permanent pacemakers, implantable cardioverter-defibrillators, or closure device. †See text for definitions. ‡At the conclusion of the Melody PPVI catheterization. §As observed at either follow-up chest radiograph or catheterization.
compared with 87% for the later-recruited patients (log-rank P=0.53 for the overall difference in event rates).
Comparison of Infection Rates With Historical RVOT Stented Cohort
Kaplan-Meier estimates of freedom from infection in the groups of patients that underwent Melody PPVI and patients who underwent a BMS implantation at the RVOT are shown in Figure 4 . During maximal follow-up of ˃ 12 years, the cumulative probability of survival without infection was 100% in patients who underwent a BMS implantation compared with 64% in those who underwent Melody PPVI during a maximal follow-up of ˃ 5 years (log-rank P<0.001 for the overall difference in event rates).
Discussion
In this single-center cohort study, we found a 9.5% incidence of bloodstream infections during a median follow-up of 19 months among patients who underwent a percutaneous Melody valve implantation at the RVOT. Among 14 patients with BSI treated with a prolonged antibiotic course, 2 deaths occurred during the course of treatment, whereas neither was thought to have involvement of the bioprosthetic valve. Four BSI patients had documentation of valve involvement by both TTE and TEE, and all patients had high gradients across the RVOT when compared with the previous evaluations. Infecting organisms were predominantly Staphylococci and Streptococci, and 8 of 14 patients had identifiable infections or exposures that may have seeded the bacteremia.
Parameters Associated With Bloodstream Infections
Demographic Parameters
In our cohort, 13 of the 14 infections occurred in male patients (93%). This strong predominance has also been reported in large series of native valve endocarditis occurring in patients with 23 and without 13 congenital heart conditions, as well as in a large series of patients with prosthetic valve endocarditis. 24 However, in 1 recent series of pediatric patients, most of whom had congenital heart disease, this sex effect was not apparent. 25 Whether sex is primarily a risk factor in predominantly adult populations is 1 possibility that could be further explored.
History of previous endocarditis was more common among patients who had BSI, with an incidence of 36% as compared with 7% among the non-BSI patients. None of the patients who had a previous endocarditis event was known to use intravenous drugs, which is an important predisposing risk factor for recurrent events. All previous endocarditis events occurred >1.5 years before the index BSI recorded for this analysis, making the possibility of relapse or dormant bacterial colonization unlikely. The possibility that previous endocarditis events create pathological vessel or myocardial lesions that partially heal over the years and, thus, promote event recurrences at the time of occult bacteremias has been suggested, 26 yet this is a mainly speculative mechanism.
Anatomic and Hemodynamic Parameters
Hemodynamic factors also seemed to play a role in BSI risk. We found that the follow-up mean gradients across the RVOT were higher among patients who had BSI. RVOT obstruction resulting in turbulent blood flow across the stenotic region, and possibly vessel wall injury, was proposed as a potential contributor to infection in the report of endocarditis involving Melody valves by Patel et al. 16 The underlying mechanism of the occurrence of infections in these patients may be related to the alteration of the vessel intima, lowering local resistance to subsequent vessel infection by blood-borne organisms. 27 In their report of the Medico-Economic Evaluation of a Nonchirurgical Pulmonary Valve Replacement Melody French experience, the authors described 4 endocarditis cases of whom 2 died during their infection event. In this report, all patients had direct valve involvement with presence of vegetations, and 3 had high gradients at the time of infection. This report suggested that abrupt discontinuation of antiaggregant treatment might have served as a precipitant of thrombus formation on the valve, serving as a site for seeding of BSI. 16 We did not identify such association in our analysis because all of the 3 patients that had BSI within 6 months of the procedure (the recommended time period for aspirin use) were still taking their aspirin at the time of the infection, by self-report. All other BSI events occurred well after the 6-month period of the aspirin administration, with the earliest event taking place 9 months after the procedure (3 months after the discontinuation of the aspirin).
One of the unique findings emerging from our study is the association between anatomic characteristics of the RVOT and subsequent BSI events. Notably, most patients in this series had homograft conduits in the RVOT with angiographic apparent irregularities of the lumen contour attributable to calcification and degeneration of the valve tissue or the sinuses. To further elucidate this association, we developed a novel diagnostic and grading method for the evaluation of RVOT wall irregularities, specifically those that created vascular spaces outside the wall of the stent of the valve. Using the developed parameters, we found that these RVOT wall irregularities, leading to areas of nonlaminar flow and possibly stasis, were more common in patients who had BSI. Sheath-to-sheath time was associated with BSI in this analysis, yet longer procedural duration did not seem to be attributable to additional interventions performed at the index catheterization. Procedural times were similar in the early and late implantation eras, suggesting that procedure times were not obviously related to the learning curve associated with the introduction of a new procedure or device. In the vast majority of cases, the vascular access was established through the groin and, thus, access site was also not associated with BSI occurrence.
Procedural Parameters
In their evaluation of >22 000 patients who had coronary intervention at catheterization, Munoz et al 28 reported an infection incidence of 0.11% and median time to infection of 1.7 days. Procedure-associated infections are unlikely in our cohort because the earliest infection occurred 28 days after the procedure, and the median time to infection was 15 months.
Comparison With Patients undergoing Different Types of RVOT Interventions
To explore whether the mere presence of a stent in the RVOT contributes to subsequent occurrence of BSI, we evaluated the incidence of BSI in a historical cohort of patients that underwent nonvalved BMS implantation at the RVOT. We found that despite considerably longer follow-up (55 versus 32 months), this cohort of patients had a 100% freedom of BSI as compared with 64% in the Melody cohort.
Several studies evaluating the long-term outcomes after surgical pulmonic valve implantation are available, although the occurrence of endocarditis was reported only in a few. 14, 15 The overall incidence of endocarditis was reportedly low, ranging between 1.2% and 2% during follow-up periods of 2 to 5 years. The incidence of BSI was not an evaluated end point. Given the findings of our study, and the fact that PPVI remains an attractive alternative to surgery, the analysis that remains to be performed is one comparing the occurrence of BSI between surgical pulmonic valve replacement and Melody PPVI.
Prosthetic Valve Endocarditis Diagnosis in Patients With RVOT Conduit
This review may underestimate the incidence of valve endocarditis because the patients diagnosed as having valve involvement were managed without valve explantation and pathological examination of the specimen, and imaging of the valve was insufficient to identify vegetations in vivo. It has been our experience that, because of the extremely anterior position of the valve in the chest, visualization of the Melody valves is better by TTE. Moreover, among patients who had BSI in our analysis who had both TTE and TEE, there were no cases in which the TEE added data that was not already available from the TTE study. We also report that in all patients with BSI, there was a significant increase in the pressure gradient across the RVOT when compared with the last studies performed before the infection. This can potentially implicate that high pressure gradient across the RVOT might be used as surrogate for the diagnosis of valvular involvement in systemic infection in this patient population.
Study Limitations
The data for this analysis was obtained from a single center. Because most patients in this cohort were enrolled in prospective trials with compulsory follow-up, it is unlikely that ours is an underestimate of the incidence of BSI. However, it is possible that infections not identified and treated as suspected endocarditis, but rather treated on an outpatient basis, may have escaped reporting. The presence of previous endocarditis events may have been underestimated in the study population because this was captured by review of available records.
The determination of valve involvement was made, when possible, by either a good quality TTE with adequate imaging of the RVOT, or by TEE. This determination is vulnerable to the limitations of echocardiographic assessment of vegetations on the pulmonary valve and, in 2 of the patients who had BSI, TEE was not performed at the time of the infection. Only a single valve was explanted at the time of the endocarditis event, and it was not sent for pathological evaluation.
Conclusions
In this cohort estimate of bloodstream bacterial infections after Melody PPVI, we identified a 9.5% incidence in a cohort of 147 consecutive patients during a median follow-up of 19 months. The median procedure to infection time was 15 months, with the earliest event occurring within the first month after implantation. The most striking finding of this study is the apparent impact of patient and nonvalve anatomic features on the incidence of post-PPVI BSI.
It is our notion that lifelong recommendation for preprocedural antibiotic prophylaxis for patients with a Melody valve who either have a history of previous endocarditis or have a complex RVOT anatomy (ie, high stent burden and deep luminal irregularities) may be advisable. For patients who are being evaluated for PPVI and who carry a combination of these risk factors, consideration should be given to standard surgical management or, in elective cases, to deferral of the PPVI until more data derived from broader community PPVI centers are available about the potential risks.
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